Patient Profile and Therapeutic Management in Glioblastoma (Gbm): a Subgroup Analysis of a Large Prospective Observational Study of the Neuro-Oncology Investigation Spanish Group (Geino)
| Autor: | M. Gil Gil, Á. Rodríguez Sánchez, J.M. Vieitez, Saulo A. Vázquez, José L. Andrade, Francisco M González V, L.M. Rodríguez, Elena Pujol, Joaquín M. Sepúlveda, Oscar Gallego |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Temozolomide Bevacizumab business.industry medicine.medical_treatment Hematology Chemotherapy regimen Dacomitinib Surgery BV Regimen chemistry.chemical_compound chemistry Internal medicine Concomitant medicine Progression-free survival business Neoadjuvant therapy medicine.drug |
| Zdroj: | Annals of Oncology. 25:iv140 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdu330.11 |
| Popis: | Aim: To date, sociodemographic data and therapeutic management have not been well explored in GBM patients (p) at Spanish level. The GEINO-10 study was designed to evaluate the clinical profile and therapeutic behaviors in p with intra-axial brain tumours (BT). GBM, the most common malignant adult tumour, is the most frequent in our database. Methods: Data on p with intra-axial BT were collected over years (2010-2013). Out of 397 p included, 67% had GBM. We aim to undertake an exploratory subanalysis of this poor prognostic group to describe the clinical and pathological characteristics as well as the therapeutic management of GBM in 28 Spanish institutions. Results: 265 p with GBM were enrolled. Median age: 61 years (19-83); male/female (%): 63/37; ECOG 0/1 (%): 23/48. 55% had comorbidity. 10% had history of previous cancer . Symptoms at diagnosis: 35% focal neurological deficit; 28% cognitive impairment; 19% epileptic seizures and 7% ataxia. Location (lobe): 32.5% frontal, 32% temporal, 15% parietal and 6% occipital. Treatment (Tx) received: 42% complete resection, 42% partial, 10% stereotactic biopsy and 6% open biopsy. 3% of p received neoadjuvant temozolomide (TMZ) ± bevacizumab (BV) into a clinical trial. 94% of p received radiotherapy (RT) (72% focal, 21% whole-brain and 6% hemi-brain) concomitant with TMZ. After the concomitant phase, 82% of p received active chemotherapy (CT) with a median of 5 cycles (1-14) and 97% of them with TMZ. Out of 188 p evaluable, a disease control rate was achieved in 70% and the median Progression Free Survival was 10.4 months (95%CI: 9-11.8). At progression, 41% of total p received Tx: 13% surgery, 8% RT and 95% CT (52% BV ± CPT11, 15.5% TMZ, 12% nitrosoureas, 4.5% dacomitinib and 9% other). Overall Survival achieved was 23.6 months (95%CI: 16-31.2). Conclusions: At diagnosis, almost all patients received RT + TMZ after surgery or biopsy. 41% were treated at progression, half of them with a BV regimen. The exceptionally good survival could reflect a selection of p with good PS. This information can be useful to homogenize and to optimize Tx and for future clinical trials in GBM. Disclosure: All authors have declared no conflicts of interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|